Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborators: Cardiome Pharma; Correvio International Sarl

Criteria

Inclusion Criteria:

• Subject must have symptomatic AF

• Subject must have adequate anticoagulant therapy

Exclusion Criteria:

• Subject may not have Class IV congestive heart failure.

• Subject may not have uncorrected electrolyte imbalance.